Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Use of immunoglobulin (Ig) in peripheral neuropathies. Impact of Ig on remission rates: comparison of intravenous immunoglobulin and subcutaneous immunoglobulin.

× No keyword cloud information.

9 in total

1. Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy.

Authors: L H Markvardsen; J-C Debost; T Harbo; S H Sindrup; H Andersen; I Christiansen; M Otto; N K Olsen; L L Lassen; J Jakobsen
Journal: Eur J Neurol Date: 2013-01-07 Impact factor: 6.089

Review 2. Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

Authors: Richard Hughes
Journal: J Clin Immunol Date: 2010-05 Impact factor: 8.317

3. Long-term therapy with high doses of subcutaneous immunoglobulin in multifocal motor neuropathy.

Authors: Thomas Harbo; Henning Andersen; Johannes Jakobsen
Journal: Neurology Date: 2010-10-12 Impact factor: 9.910

4. Long-term treatment of Lewis-Sumner syndrome with subcutaneous immunoglobulin infusions.

Authors: Antonios Bayas; Ralf Gold; Markus Naumann
Journal: J Neurol Sci Date: 2012-10-23 Impact factor: 3.181

5. Subcutaneous vs intravenous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy: an Italian cost-minimization analysis.

Authors: Carlo Lazzaro; Leonardo Lopiano; Dario Cocito
Journal: Neurol Sci Date: 2014-01-28 Impact factor: 3.307

6. Subcutaneous immunoglobulin therapy for multifocal motor neuropathy.

Authors: Filip Eftimov; Marinus Vermeulen; Rob J de Haan; Leonard H van den Berg; Ivo N van Schaik
Journal: J Peripher Nerv Syst Date: 2009-06 Impact factor: 3.494

7. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial.

Authors: Richard A C Hughes; Peter Donofrio; Vera Bril; Marinos C Dalakas; Chunqin Deng; Kim Hanna; Hans-Peter Hartung; Norman Latov; Ingemar S J Merkies; Pieter A van Doorn
Journal: Lancet Neurol Date: 2008-02 Impact factor: 44.182

8. Long-term outcome in chronic inflammatory demyelinating polyneuropathy patients treated with intravenous immunoglobulin: a retrospective study.

Authors: Luis Querol; Ricard Rojas-Garcia; Carlos Casasnovas; Maria Jose Sedano; Jose Luis Muñoz-Blanco; Maria Antonia Alberti; Carmen Paradas; Teresa Sevilla; Julio Pardo; Jose Luis Capablo; Rafael Sivera; Antonio Guerrero; Eduardo Gutierrez-Rivas; Isabel Illa
Journal: Muscle Nerve Date: 2013-09-11 Impact factor: 3.217

9. Efficacy and safety of Privigen(®) in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study).

Authors: Jean-Marc Léger; Jan L De Bleecker; Claudia Sommer; Wim Robberecht; Mika Saarela; Jerzy Kamienowski; Zbigniew Stelmasiak; Orell Mielke; Björn Tackenberg; Amgad Shebl; Artur Bauhofer; Othmar Zenker; Ingemar S J Merkies
Journal: J Peripher Nerv Syst Date: 2013-06 Impact factor: 3.494

9 in total